Eugenosedin-A improves glucose metabolism andinhibits MAPKs expression in streptozotocin/nicotinamide-induced diabetic rats

MUIR > Graduate Institute of Health Care > Department of Nursing > Papers > Item 987654321/3535

Please use this identifier to cite or link to this item: http://ir.meiho.edu.tw/ir/handle/987654321/3535

Title:	Eugenosedin-A improves glucose metabolism andinhibits MAPKs expression in streptozotocin/nicotinamide-induced diabetic rats
Authors:	Shen, Kuo-Ping;Lin, Hui-Li;Yen, Hsueh-Wei;Hsieh, Su-Ling;An, Li-Mei;Wu, Bin-Nan
Keywords:	Eugenosedin-A;Type II diabetes;mellitus;Insulin;Glucose metabolism;MAPKs pathway
Date:	2018-04-18
Issue Date:	2018-04-18T05:36:40Z (UTC)
Abstract:	This study examined the effects of eugenosedin-A (Eu-A) in a streptozotocin (STZ)/ nicotinamide-induced rat model of type II diabetes mellitus (T2DM). Six-week-old Spraguee Dawley rats were randomly divided into three groups: (1) RD group, normal rats fed a regular diet (RD), (2) DM group, T2DM rats fed a high-fat diet, and (3) Eu-A group, T2DM rats fed a high fat diet plus oral Eu-A (5 mg/kg/day). After 30 days, the DM group had higher body weight, higher blood glucose and lower insulin levels than the RD group. The DM group also had increased protein expression of glycogen synthase kinase (GSK) in liver and skeletal muscle and decreased protein expression of insulin receptor (IR), insulin receptor substrate-1 (IRS- 1), IRS-2, AMP-activated protein kinase (AMPK), glucose transporter-4 (GLUT-4), glucokinase (GCK), and peroxisome proliferator-activated receptor g (PPAR-g). STZ/nicotinamideinduced T2DM increased the expression of mitogen-activated protein kinases (MAPKs: p38, ERK, JNK) and inflammatory p65 protein. In the Eu-A treated T2DM rats, however, blood
Appears in Collections:	[Department of Nursing] Papers

Files in This Item:

File	Description	Size	Format
沈國屏2018-KJMS (Eu-A).pdf		645Kb	Adobe PDF	1	View/Open

View Licence